Samsung BioLogics seek to raise over W2tr via IPO

[THE INVESTOR] Samsung BioLogics is expected to raise up to 2.25 trillion won (US$2.04 billion) through its planned initial public offering next month, which will be the third-largest stock sale in the country’s history.

According to a securities registration statement of Samsung Group’s biopharmaceutical contract manufacturing arm on Oct. 4, it will seek to sell some 16.54 million shares at 113,000 won to 136,000 won.

If the company prices its IPO at the top end of its proposed range, it could raise 2.249 trillion won. 

It will take investor orders on Nov. 2-3.

By Park Han-na (hnpark@heraldcorp.com)